Tretinoin
Small molecule targets CD38, CD55, CD59, CYP26A1, HOXA3, HOXA4, HOXA5, NPM1, PBX3, PML, RARA via activation
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VESANOID | — | 2023-02-21 | fda.gov ↗ |
| Label expansion | US (FDA) | RETIN-A-MICRO | — | 2002-05-10 | fda.gov ↗ |
| Label expansion | US (FDA) | RENOVA | — | 2000-08-01 | fda.gov ↗ |
| Approved | US (FDA) | RETIN-A | — | 1971-10-20 | fda.gov ↗ |
Trials 171 · started per year
Also used as a comparator or background therapy in 62 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03433378 Comparator | Aug 2017 → Jan 2018 | acne | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT04059523 Comparator | Jun 2019 → Feb 2020 | acne | Sol-Gel Technologies, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04206631 Comparator | Apr → Sep 2015 | acne | Indonesia University | Completed | No outcome recorded |
| Phase 1 | NCT01161550 Background | Nov 2010 → Aug 2011 | acute myeloid leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00604032 Comparator | Jan 2008 | — | Coria Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00195156 Background | Jul 2003 → ? | high grade malignant neoplasm | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02712905 Background | May 2016 → Apr 2022 | hematopoietic and lymphoid system neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02717884 Background | May 2015 → Dec 2020 | acute myeloid leukemia, myelodysplastic syndrome | Michael Luebbert | Unknown | No outcome recorded |
| Phase 1/2 | NCT00919555 Comparator | Jun 2008 → Nov 2009 | amyotrophic lateral sclerosis | Phoenix Neurological Associates, LTD | Completed | No outcome recorded |
| Phase 216 trials | ||||||
| Phase 2 | NCT07366229 Comparator | Dec 2025 → Mar 2026 overdue | acne | Shenzhen People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05461755 Comparator | Nov 2022 → Jul 2023 | dermis disorder | Merete Haedersdal | Completed | No outcome recorded |
| Phase 2 | NCT06013540 Background | Aug → Dec 2022 | hyperpigmentation of the skin | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
| Phase 2 | NCT04687176 Background | Jan 2021 → Dec 2025 overdue | acute promyelocytic leukemia | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT04396067 Comparator | Oct 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04080869 Comparator | Jan → Aug 2020 | acne | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03624270 Background | Aug 2018 → Sep 2023 | acute promyelocytic leukemia | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 2 | NCT02278861 Comparator | Nov 2011 → Apr 2014 | actinic keratosis | Federal University of Goiás | Completed | No outcome recorded |
| Phase 2 | NCT01283464 Comparator | Nov 2010 → Dec 2011 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00842907 Comparator | May → Dec 2009 | radiation-induced disorder | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2 | NCT01085279 Comparator | Mar 2009 → Feb 2010 | skin pigmentation disorder | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 2 | NCT00621218 Comparator | Feb → Apr 2008 | rosacea | Coria Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00514293 Background | Jan 2007 → Dec 2011 | lung cancer | Raghu Nandan, M.D., Inc | Unknown | No outcome recorded |
| Phase 2 | NCT00276601 Background | Oct 2004 → Dec 2007 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00100906 Comparator | Aug 2004 → Jun 2006 | kidney cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00136461 Background | May 1997 → Aug 2000 | acute myeloid leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07084116 Comparator | Jul 2025 → May 2026 | purpura, skin atrophy | James Thomas Pathoulas | Completed | No outcome recorded |
| Phase 2/3 | NCT06787222 Comparator | Nov 2024 → Aug 2025 overdue | acne | Hasanuddin University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00717652 Background | Jul 2008 | hyperpigmentation of the skin | Azidus Brasil | Suspended | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07504458 Background | Jun 2026 → Mar 2027 expected | acute promyelocytic leukemia | Quetzal Therapeutics | Recruiting | No outcome recorded |
| Phase 3 | NCT07296445 Background | Jan 2026 → Jun 2027 expected | acute myeloid leukemia, t(15;17)(q24;q21), acute promyelocytic leukemia | SDK Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07503730 Background | Jun 2025 → Jun 2028 expected | acute promyelocytic leukemia | First Affiliated Hospital Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 3 | NCT06447480 Comparator | Apr 2025 → Sep 2026 expected | acne | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 3 | NCT02899169 Background | Sep 2016 → Sep 2022 | acute promyelocytic leukemia | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT01406080 Comparator | Jan 2013 → Nov 2015 | hyperpigmentation of the skin, radiation-induced disorder | Galderma Brasil Ltda. | Completed | No outcome recorded |
| Phase 3 | NCT00893399 Background | May 2010 → Sep 2021 | acute myeloid leukemia | University of Ulm | Completed | No outcome recorded |
| Phase 3 | NCT01125930 Comparator | May 2010 → Jan 2013 | rosacea | Lisa E. Maier | Terminated | No outcome recorded |
| Phase 3 | NCT00647556 Comparator | Apr 2008 → Jan 2010 | hyperpigmentation of the skin | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT00482833 Background | Aug 2007 → Sep 2012 | leukemia | GIMEMA Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00962767 Comparator | May 2002 → Dec 2007 | acute myeloid leukemia | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00003934 Background | Jun 1999 → Nov 2006 | acute myeloid leukemia, t(15;17)(q24;q21), acute promyelocytic leukemia, childhood acute myeloid leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00007631 Comparator | Mar 1998 → Nov 2004 | basal cell carcinoma, skin neoplasm, squamous cell carcinoma | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07012811 Comparator | Feb 2024 → Mar 2025 | skin disorder caused by infection | Latakia University | Completed | No outcome recorded |
| Phase 4 | NCT02731105 Comparator | Feb 2015 → Feb 2017 | acne | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 4 | NCT01987297 Background | Jun 2012 → Dec 2020 | acute promyelocytic leukemia | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT01522456 Comparator | Apr → May 2012 | acne | Galderma R&D | Completed | No outcome recorded |
| Phase 4 | NCT02200978 Background | Sep 2011 → Oct 2021 | acute promyelocytic leukemia | South China Children's Leukemia Group | Completed | No outcome recorded |
| Phase 4 | NCT01422785 Comparator | Jul → Dec 2011 | acne | Zeichner, Joshua, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT01313728 Comparator | Dec 2010 | acne | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01149876 Comparator | Jun 2010 → Dec 2011 | hyperpigmentation of the skin | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00939133 Comparator | Jul 2009 → Dec 2010 | acne | Dermatrials Research | Completed | No outcome recorded |
| Phase 4 | NCT01047189 Comparator | Mar → Oct 2009 | acne | Wake Forest University | Completed | No outcome recorded |
| Phase 4 | NCT01027793 Comparator | Mar 2009 → Aug 2010 | striae distensae, familial | Hexsel Dermatology Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00835198 Comparator | Dec 2008 → Aug 2009 | acne | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00669071 Comparator | Jan → Oct 2008 | hyperpigmentation of the skin | Galderma R&D | Terminated | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07485777 Comparator | Jul → Dec 2026 expected | hyperpigmentation of the skin | Foundation University Islamabad | Not yet recruiting | No outcome recorded |
| — | NCT07345507 Comparator | Feb → Aug 2025 | hyperpigmentation of the skin | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| — | NCT06181838 Comparator | Aug → Nov 2023 | acne | Indonesia University | Unknown | No outcome recorded |
| — | NCT05710068 Background | Dec 2021 → Aug 2022 | hyperpigmentation of the skin | Ajou University School of Medicine | Completed | No outcome recorded |
| — | NCT04835259 Comparator | Apr 2021 → Apr 2022 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT02704507 Background | Jun 2015 → Jan 2016 | acne | Carilion Clinic | Unknown | No outcome recorded |
| — | NCT01335581 Background | Apr 2011 → Mar 2012 | mixed dermis disorder | ConBio, a Cynosure Company | Completed | No outcome recorded |
| — | NCT00974480 Comparator | Sep 2009 → Jul 2010 | skin atrophy | Cosmetique Active International | Completed | No outcome recorded |
Evidence & citations 44 cited values
Every value below carries the sentence it was read from. 246 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tretinoin | “METHODS: This 16-week, two-center, investigator-blinded, randomized, parallel-group study evaluated the antimicrobial efficacy of clindamycin phosphate 1%/benzoyl peroxide 5%...” PMID 20214175 ↗ Feb 2010117“Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion in subjects with moderate...” NCT02849860 ↗ “This study was a prospective, two-arm, multicenter clinical trial to evaluate the efficacy and safety of tretinoin capsules combined with azacitidine and venetoclax in the...” NCT06841952 ↗ “Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around...” NCT06516419 ↗ “Apply triple combination cream containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1...” NCT06780644 ↗ “Participants received modified Kligman's formula consisting of hydroquinone 4%, tretinoin 0.05%, and mometasone furoate 0.1% immediately after standardized microneedling with a...” NCT07696806 ↗ “HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).” NCT05386823 ↗ “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02932306 ↗ “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02965456 ↗ “Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)” NCT04835259 ↗ “Kligman's regimen - a combination of hydroquinone, tretinoin, and fluocinolone acetonide - remains the gold standard for treatment” NCT07485777 ↗ “Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%” NCT04118296 ↗ “Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.” NCT02850003 ↗ “Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.” NCT01522456 ↗ “topical tretinoin or adapalene once daily (every other day if irritation) with doxycycline or lymecycline 100 mg/d” NCT06447480 ↗ “Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks” NCT00689117 ↗ “Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)” NCT03761784 ↗ “Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks” NCT01085279 ↗ “Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days.” NCT00891982 ↗ “5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months” NCT05710068 ↗ “Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.” NCT00838812 ↗ “ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration.” NCT02177812 ↗ “Tretinoin is a topical medication that is known to improve photodamage.” NCT01125930 ↗ “tretinoin cream 0.05% on face every night” NCT04206631 ↗ “Toremifene, Tretinoin, Vandetanib” NCT02788201 ↗ “Clindamycin 1%, Tretinoin 0,025%” NCT02731105 ↗ “Topical 0.05% Tretinoin” NCT06008327 ↗ “Trametinib Tretinoin” NCT02551718 ↗ |
| Known as | Aberel | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Acretin 0.05% cream | “Topical application of a retinoid (tretinoin 0.05%) cream once daily at night for 6 months (Acretin 0.05% cream Jamjoom pharmaceuticals, Egypt)” NCT04835259 ↗ |
| Known as | Acticin | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | All-trans retinoic acid | “Recent laboratory data have shown that all-trans-retinoic acid, a derivative of vitamin A, can regenerate alveoli in adult rats with elastase induced emphysema (Massaro, GD and...” NCT00000621 ↗98“Acute promyelocytic leukemia (APL) is highly curable with the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy (CT), but very long-term...” PMID 20018913 ↗ Dec 2009 “HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL)...” NCT05388487 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “This study is a prospective, double-blind, multicenter, randomized controlled phase II clinical trial of tislelizumab combined with chemotherapy and all trans retinoic acid in...” NCT06703047 ↗ “PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in...” NCT01409161 ↗ “The purpose of this research study is to learn if adding all-trans retinoic acid (tretinoin) to conventional treatment of Anti- Neutrophil Cytoplasmic Autoantibodies (ANCA)...” NCT01275274 ↗ “Effect of All-trans Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer and...” NCT01041833 ↗ “Patients aged ⩾60 years reported to the PETHEMA registry and were treated with all-trans retinoic acid (ATRA) plus anthracycline-based regimens according to three consecutive...” PMID 28584252 ↗ Jun 2017 “a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ) and all-trans retinoic acid (ATRA) induced...” PMID 30542286 ↗ Nov 2018 “A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed...” NCT04700176 ↗ “Tretinoin is a vitamin A derivative (all-trans retinoic acid) that has been used by dermatology for more than five decades and is currently approved for the management of...” NCT06358677 ↗ “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ “This randomized phase II trial evaluated whether the combination of cisplatin and paclitaxel plus All-trans retinoic acid (ATRA) increases Response rate (RR) and...” NCT01048645 ↗ “All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone.” PMID 10438706 ↗ Aug 1999 “dietary supplementation with all-trans retinoic acid (ATRA) has been shown to significantly ameliorate autism-like behaviors caused by UBE3A overexpression in male mice .” NCT07079696 ↗ “All trans retinoic acid 20 mg bid, orally, D-3-D11, administered continuously for 14 days, stopped for 7 days, with one course of treatment lasting 21 days.” NCT06636981 ↗ “In Acute Promyelocytic Leukemia (APL, AML M3), all-trans-retinoic-acid (ATRA; Tretinoin) induces differentiation and subsequently clinical remission.” NCT02261779 ↗ “All-trans retinoic acid (ATRA) will be administered orally as frontline treatment for patients with active hemophagocytic lymphohistiocytosis (HLH).” NCT07626398 ↗ “A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor” NCT00001509 ↗ “all trans retinoic acid (ATRA) combined with danazol was effective in the treatment of refractory immune thrombocytopenic purpura (ITP)” NCT04324411 ↗ “All-trans retinoic acid, will be administered by mouth (PO) from the first day at a dose of 45 mg/m²/day, fractionated into 2 doses.” NCT00465933 ↗ “As all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are widely accepted in treating acute promyelocytic leukemia (APL)” PMID 33495363 ↗ Feb 2021 “Patients will be recruited to oral arsenic trioxide, all-trans-retinoic acid, ascorbic acid (AAA) based-induction for 42 days.” NCT04687176 ↗ “Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes” NCT00382200 ↗ “2. All-trans retinoic acid (RA) has beneficial effects when used in a variety of inflammatory skin conditions.” NCT04396067 ↗ “2. All-trans retinoic acid (RA) has beneficial effects when used in a variety of inflammatory skin conditions.” NCT04396067 ↗ “in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid leukemia (AML)” NCT04282668 ↗ “All trans retinoic acid: provided free of charge by Shandong Liangfu Pharmaceutical Co., Ltd.” NCT07355855 ↗ “All-trans-retinoic acid: provided free of charge by Shandong Liangfu Pharmaceutical Co., Ltd.” NCT07355855 ↗ “all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28)” PMID 27036160 ↗ Apr 2016 “The first medicine is tretinoin (also called all-trans retinoic acid, ATRA, or Vesanoid).” NCT01404949 ↗ “All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks)” NCT01882127 ↗ “plus all-trans retinoic acid (ATRA) followed by three consolidation cycles” PMID 37187198 ↗ May 2023 “Coformulation Favezelimab/Pembrolizumab + All-trans Retinoic Acid (ATRA)” NCT04305054 ↗ “All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle” NCT01369368 ↗ “All-trans retinoic acid (ATRA) is included in all phases of therapy” NCT01226303 ↗ “all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses)” NCT03624270 ↗ “repurposing All Trans Retinoic Acid (ATRA) to target the stroma” PMID 39833722 ↗ Jan 2025 “All-trans retinoic acid (Vesanoid) 45 mg/m2 on days 1-14.” NCT05482451 ↗ “liposome encapsulated all-trans retinoic acid (ATRA-IV)” NCT00195156 ↗ “All-trans retinoic acid, oral, for 4 weeks (Days 0-28).” NCT07503730 ↗ “liposome encapsulated all-trans retinoic acid (ATRA-IV)” NCT00195156 ↗ “Tretinoin, All-trans-Retinoic Acid, TRA, NSC-122758.” NCT00002479 ↗ “fixed-dose ATRA (all-trans-retinoic acid)” NCT02717884 ↗ “All-trans-retinoic-acid (ATRA; oral)” NCT07504458 ↗ “all trans retinoic acid” NCT05175508 ↗ |
| Known as | all-trans retinoic acid (ATRA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02751255 ↗ |
| Known as | All-Trans Retonoic Acid | “Decitabine and All-Trans Retonoic Acid (Tretinoin)” NCT00382200 ↗ |
| Known as | Altreno | “tretinoin 0.05% lotion (Altreno)” NCT04096742 ↗ |
| Known as | ATRA | “This is an open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of...” NCT06158412 ↗74“HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL)...” NCT05388487 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients...” NCT04433169 ↗ “PRIMARY OBJECTIVES: I. Assess whether a combination of all-trans retinoic acid (ATRA [tretinoin]), and arsenic trioxide (ATO) can produce long-term event-free survival in...” NCT01409161 ↗ “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ “Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1.” NCT00482833 ↗ “All-Trans Retinoic Acid (ATRA) is an oxidative metabolite of retinol (vitamin A) and plays an important role in the regulation of cellular proliferation and differentiation.” NCT06536413 ↗ “All-trans Retinoic Acid (ATRA)-Based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment of High-risk Relapsed/Refractory B-NHL Ineligible for High-dose Chemotherapy” NCT06646666 ↗ “All-Trans Retinoic Acid (ATRA) is administered orally, twice daily, as part of standard induction and consolidation therapy for acute promyelocytic leukemia.” NCT07187505 ↗ “In Acute Promyelocytic Leukemia (APL, AML M3), all-trans-retinoic-acid (ATRA; Tretinoin) induces differentiation and subsequently clinical remission.” NCT02261779 ↗ “All-trans retinoic acid (ATRA) will be administered orally as frontline treatment for patients with active hemophagocytic lymphohistiocytosis (HLH).” NCT07626398 ↗ “induction therapy comprising tretinoin (ATRA) and arsenic trioxide (ATO) (along with idarubicin in patients with leukocytosis)” NCT00528450 ↗ “All-trans retinoic acid (ATRA) has an immunomodulatory effect on haemopoiesis, making it a possible treatment option.” PMID 28917657 ↗ Sep 2017 “In vitro treatment of normal human monocytes with all-trans retinoic acid (ATRA) down-regulates TLR-2 expression (58)” NCT04396067 ↗ “An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis” NCT03359174 ↗ “All-trans retinoic acid (ATRA) 45mg/m2 orally in two equally divided doses on days 1-14 of each 28-day cycle” NCT05345002 ↗ “All-trans retinoic acid (ATRA) is mandatory in the treatment of acute promyelocytic leukaemia (APL).” PMID 18922099 ↗ Nov 2008 “6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)” NCT01237808 ↗ “ATRA (all-trans retinoic acid) and derivatives (retinoids) are promising anticancer agents” NCT04113863 ↗ “The first medicine is tretinoin (also called all-trans retinoic acid, ATRA, or Vesanoid).” NCT01404949 ↗ “all-trans retinoic acid (ATRA) plus low-dose rituximab (LD-RTX) with LD-RTX monotherapy” PMID 34665865 ↗ Jan 2022 “all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses)” NCT03624270 ↗ “all-trans retinoic acid (ATRA) in combination with chemotherapy” PMID 27696203 ↗ Oct 2016 “Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim” NCT00893399 ↗ “all-trans retinoic acid (ATRA) and idarubicin (AIDA)” NCT00465933 ↗ “The medication is all-trans retinoic acid (ATRA).” NCT01456468 ↗ “Drug: all-trans retinoic acid (ATRA)” NCT02712905 ↗ “Drug: All-Trans Retinoic Acid (ATRA)” NCT00326170 ↗ “All -trans Retinoic Acid (ATRA)” NCT00617409 ↗ “all-trans-retinoic acid (ATRA)” NCT04687176 ↗ “all-trans retinoic acid (ATRA)” NCT07503730 ↗ “all-trans retinoic acid (ATRA)” NCT07296445 ↗ “All-Trans Retinoic Acid (ATRA)” NCT00413166 ↗ “all-trans retinoic acid (ATRA)” NCT01064570 ↗ “all-trans retinoic acid (ATRA)” NCT01064557 ↗ “all-trans retinoic acid (ATRA)” NCT00995332 ↗ “all-trans retinoic acid (ATRA)” NCT02751255 ↗ “All-Trans Retinoic Acid (ATRA)” NCT01161550 ↗ “all-trans retinoic acid (ATRA)” NCT07597395 ↗ “All-Trans Retinoid Acid(ATRA)” NCT01882127 ↗ “tretinoin (ATRA)” NCT00002701 ↗ “Vesanoid (ATRA)” NCT01067274 ↗ |
| Known as | ATRA-IV | “liposome encapsulated all-trans retinoic acid (ATRA-IV)” NCT00195156 ↗ |
| Known as | Atralin | “We want to find out if Atralin (tretinoin 0.05%) Gel used for up to 46 weeks will improve erythematotelangiectatic rosacea (ETR).” NCT01125930 ↗3“A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea” NCT00621218 ↗ “Atralin (tretinoin) Gel, 0.05%” NCT00604032 ↗ “Atralin (tretinoin) gel, 0.05%” NCT00603772 ↗ |
| Known as | Avita | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | E-ATRA | “Encapsulated Benzoyl Peroxide (E-BPO) and Encapsulated Tretinoin (E-ATRA) Cream, (E-BPO/E-ATRA Cream)” NCT03761784 ↗ |
| Known as | Eudyna | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | IDP 121 Lotion | “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02965456 ↗ |
| Known as | IDP-121 | “IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.” NCT02932306 ↗ |
| Known as | Kerlocal | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Liposomal Tretinoin | “PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.” NCT00003656 ↗1“Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease” NCT00005969 ↗ |
| Known as | NSC-122758 | “Tretinoin, All-trans-Retinoic Acid, TRA, NSC-122758.” NCT00002479 ↗ |
| Known as | Oristar rna | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Renova | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | RETIN-A | “RETIN-A® (Tretinoin) Cream (Valeant)” NCT03427554 ↗ |
| Known as | RETIN-A MICRO | “RETIN-A MICRO ® (Tretinoin) Gel Microsphere, 0.04% (Reference Listed Drug)” NCT07469228 ↗3“RETIN-A MICRO (Tretinoin Gel) Microsphere, 0.04% in a Pump Dispenser” NCT00907257 ↗ “RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% (Valeant)” NCT04883736 ↗ |
| Known as | retinoic acid | “Topical tretinoin (retinoic acid) has been well established to be effective for skin pigmentary disorders including melasma.” NCT03933774 ↗ |
| Known as | TRA | “Tretinoin, All-trans-Retinoic Acid, TRA, NSC-122758.” NCT00002479 ↗ |
| Known as | Trans-Retinoic acid | “This is an open-label clinical trial study that aims to evaluate the efficacy (eg. Complete response, Overall Survival, Progression Free Survival) and adverse effects of...” NCT06158412 ↗ |
| Known as | Tretin-x | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Tretinoin component of solage | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Tretinoin component of tri-luma | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Tretinoin component of twyneo | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Tretinoin component of veltin | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Tretinoin component of ziana | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | tretinoin liposome | “Patients receive tretinoin liposome IV over 30 minutes once weekly and interferon alfa-2b subcutaneously on five consecutive days (M-F) for 8 weeks.” NCT00003656 ↗ |
| Known as | Tretinoina | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | Tretinoine | ChEMBL registry synonym — accepted as the source's own label CHEMBL38 ↗ |
| Known as | VESANOID | “The first medicine is tretinoin (also called all-trans retinoic acid, ATRA, or Vesanoid).” NCT01404949 ↗ |
| Action | Inhibit | “inhibits HPV E6/E7 gene expression” NCT00003598 ↗ |
| Modality | Other / unclassified | “ATRA is a biological agent that has been shown to induce cell differentiation in leukemia cell lines” NCT00326170 ↗ |
| Modality | Small molecule | — CHEMBL38 ↗ |
| Route | Oral | “oral tretinoin (ATRA)” NCT00002701 ↗ |
| Target | HOXA3 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |
| Target | HOXA4 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |
| Target | HOXA5 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |
| Target | PBX3 | “ATRA modulates HOX activity (i.e. decreased expression of HOXA3, HOXA4 and HOXA5 and their regulator PBX3)” PMID 28877686 ↗ Sep 2017 |